Longevity Biotech (LBT) has been awarded a Phase I SBIR Contract from the National Heart, Lung, and Blood Institute (NHLBI) to further the development of the 5A apoA-I mimetic peptide program for the treatment of severe asthma.
The overall goal of this project is to prepare an inhalational 5A apoA-I mimetic peptide that will become the subject of a future Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) initially focused on patients who do not respond to standard corticosteroid treatment.
"We are honored to be selected by the NHLBI/NIH to help develop this program, which expands both our immunological portfolio as well as our capabilities in less-invasive peptide delivery," said Dr. Scott Shandler, Ph.D., co-founder and chief executive officer of Longevity Biotech.
This project has been fully funded with federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN268201700022C.